1. AMYLIN PHARMACEUTICALS (AMLN) www.amylin.comwww.amylin.com Recent stock price: 21.87 (1/19/04 close) 52-week range: 13.73- 30.75 Market cap: 2.04 Bil Revenue: $13 Mil Expenses: ($119) Mil Net Loss: ($109) Mil P/E: N/A EPS: -1.51 Estimated target price: 27.3 Amylin Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative medicines to improve the lives of people with metabolic diseases. Estimated 177 Mil people worldwide suffer from diabetes, 18 Mil of which have type I diabetes (juvenile, autoimmune), and 159 Mil have type 2 (adult). Approx. 11.5 Mil in U.S. have diabetes, with 1 Mil new cases each year. 10-Q 8K pos. results invest for Exenatide @ 25 SEC Exenatide PIII results reported

2. GS conf. Call: Amylin CEO discusses FDA rejection of Symlin Amylin announces SEC investigation of conf. call violation of Regulation FD Amylin announces positive P-III results for Exenatide Club Biomed buys 200 shrs AMLN @ ~ 25

3. AMLN v AMEX BIOTECH INDEX AMLN v NASDAQ BIOTECH INDEX January 2003-2004

4. PATENTS Hold 36 U.S. Patents and 33 pending U.S. patent applications: 17 issued to development and commercialization of SYMLIN (10 pending) 1 issued to development and commercialization of EXENATIDE (15 pending) Includes SYMLIN and amylin analogs or agonists, methods of synthesis for these molecules, methods of preparing these products, BUT DO NOT have composition-of-matter patent for EXENATIDE or EXENATIDE LAR.